By Fineline Cube Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed in a Phase Ib/III clinical trial in China evaluating JAB-23E73, an orally administered pan-KRAS inhibitor, in combination with nab-paclitaxel and gemcitabine for the first-line treatment of KRAS-mutated pancreatic cancer.
Clinical Development Overview
| Item | Detail |
|---|---|
| Company | Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) |
| Trial Phase | Phase Ib/III |
| Geography | China |
| Patient Population | First-line KRAS-mutated pancreatic cancer |
| Combination Regimen | JAB-23E73 + nab-paclitaxel + gemcitabine |
| Dosing Milestone | First patient dosed on 20 Jul 2026 |
| Next Milestone | Phase Ib safety data expected Q1 2027 |
Drug Profile & Therapeutic Rationale
- Molecule: JAB-23E73 – orally administered pan-KRAS inhibitor
- Target: Pan-KRAS inhibition (all common KRAS mutations)
- Innovation: Addresses one of oncology’s most challenging targets with high unmet need
- Intellectual Property: Independently developed by Jacobio with global patent protection
- Therapeutic Rationale: KRAS mutations show extremely high incidence in pancreatic cancer (>90% of cases), historically considered “undruggable”
Strategic Partnership Framework
| Aspect | Arrangement |
|---|---|
| Global Rights (ex-China) | Exclusive license granted to AstraZeneca (NYSE: AZN) |
| Mainland China | Joint development and commercialization by Jacobio and AstraZeneca |
| Commercial Implications | Leverages AstraZeneca’s global oncology expertise while maintaining Jacobio’s strong China presence |
| Revenue Sharing | Not disclosed; typical co-development structure for China market |
Market Context & Opportunity
- Pancreatic Cancer Landscape: One of the most lethal malignancies with five-year survival rate below 10%
- KRAS Prevalence: Mutations present in >90% of pancreatic ductal adenocarcinoma cases
- Current Treatment Gap: Limited effective targeted therapies for KRAS-mutated pancreatic cancer
- Competitive Positioning: JAB-23E73 represents one of the few pan-KRAS inhibitors in late-stage clinical development globally
- Market Potential: Global pancreatic cancer therapeutics market projected to reach $4.2 billion by 2030, with KRAS-targeted therapies commanding premium pricing
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, partnership arrangements, and market opportunities for JAB-23E73. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive dynamics, and partnership execution.-Fineline Info & Tech